首页> 美国卫生研究院文献>Immunology >Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2·1/Kb transgenic mice
【2h】

Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2·1/Kb transgenic mice

机译:HLA-A2单链三聚体呈递的乙型肝炎病毒核心抗原表位在HLA-A2·1 / Kb转基因小鼠中诱导功能性表位特异性CD8 + T细胞反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The potency of CD8+ cytotoxic T lymphocyte (CTL) responses toward core antigen has been shown to affect the outcomes of hepatitis B virus (HBV) infection. Since single-chain trimers (SCT) composed of peptide epitope β2-microglobulin (β2m) and major histocompatiblity complex (MHC) class I heavy chain covalently linked together in a single molecule have been shown to stimulate efficient CTL responses, we investigated the properties of human leucocyte antigen (HLA)-A2 SCTs encoding the HBV core antigen (HBcAg) epitopes C18−27 and C107−115. Transfection of NIH-3T3 cells with pcDNA3.0-SCT-C18−27 and SCT-C107−115 leads to stable presentation of HBcAg epitopes at the cell surface. HLA-A2.1/Kb transgenic mice vaccinated with the SCT constructs, either as a DNA vaccine alone or followed by a boost with recombinant vaccinia virus, were shown to generate HBcAg-specific CTL responses by enzyme-linked immunospot assay (ELISPOT) and in vitro interferon-γ release experiments. HBcAg-specific CTLs from vaccinated HLA-A2.1/Kb transgenic mice were able to inhibit HBV surface and e antigen expression as indicated by HepG2.2.15 cells. Our data indicate that a DNA vaccine encoding a human HLA-A2 SCT with HBV epitopes can lead to stable, enhanced HBV core antigen presentation, and may be useful for the control of HBV infection in HLA-A2-positive HBV carriers.
机译:研究表明,CD8 + 细胞毒性T淋巴细胞(CTL)对核心抗原的反应能力会影响乙型肝炎病毒(HBV)感染的结果。由于由肽表位β2-微球蛋白(β2m)和主要组织相容性复合物(MHC)I类重链共价连接在一个分子中的单链三聚体(SCT)已显示出可刺激有效的CTL反应,因此我们研究了人白细胞抗原(HLA)-A2 SCT,编码HBV核心抗原(HBcAg)表位C18-27和C107-115。用pcDNA3.0-SCT-C18-27和SCT-C107-115转染NIH-​​3T3细胞可导致HBcAg表位稳定呈现在细胞表面。用酶联免疫斑点测定法(ELISPOT)和单独的DNA疫苗接种了SCT构建体的HLA-A2.1 / Kb转基因小鼠,或单独接种重组痘苗病毒后,均产生了HBcAg特异性CTL反应。体外γ-干扰素释放实验。如HepG2.2.15细胞所示,来自接种HLA-A2.1 / Kb转基因小鼠的HBcAg特异性CTL能够抑制HBV表面和e抗原表达。我们的数据表明,编码具有HBV表位的人HLA-A2 SCT的DNA疫苗可导致稳定,增强的HBV核心抗原呈递,并且可能对控制HLA-A2阳性HBV携带者的HBV感染有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号